Generics Bulletin is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Francesca Bruce

Francesca Bruce has been writing news and analysis about all things affecting the pharmaceutical industry since 2008. She has paid special attention to policy and regulatory developments but particularly likes to write about market access and how medicines may  - or may not  -  make it to patients. She generally writes about Europe, but really enjoys uncovering news from further corners of the globe, especially Latin America and the Middle East.
Advertisement
Set Alert for Articles By Francesca Bruce

Latest From Francesca Bruce

Scotland Greenlights More Rare Disease Treatments

Scotland’s health technology appraisal body has OKd Alynlam’s Onpattro, AstraZeneca's Imfinzi and Takeda’s Alunbrig for use on the Scottish National Health Service.

Europe United Kingdom

Compulsory License On Table In UK For Orkambi

The UK government will consider all options to improve access to Vertex’s cystic fibrosis treatment, including compulsory licensing.

Europe United Kingdom

Canada Moves To Boost Biosimilar Market

Biosimilar uptake in Canada is expected to benefit from moves to switch patients onto biosimilars and the removal of health technology appraisal reviews from the process for listing drugs on public plans.

Canada North America

UK Buyers Club Aims For Lower-Cost Cystic Fibrosis Drugs

A buyers club in the UK is planning to import generic versions of Vertex’s cystic fibrosis drugs that are not available on the NHS.  Some commentators think such clubs may become more common.

Europe United Kingdom

Argentina Joins International Pharmaceutical Regulators Programme

Argentina’s drug regulator has become the newest member of the International Pharmaceutical Regulators Programme.

UK Buyers Club To Get Lower Cost Versions Of Vertex’s CF Drugs

A buyers club in the UK is planning to import generic versions of Vertex’s cystic fibrosis drugs that are not available on the NHS.  Some commentators think such clubs may become more common.

Europe United Kingdom
See All
Advertisement
UsernamePublicRestriction

Register